Analysts Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $52.33.

Several equities research analysts have recently commented on the company. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Raymond James restated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Scotiabank lifted their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a “sector outperform” rating in a report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Finally, Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th.

Insider Activity at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth about $37,000. Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. CWM LLC increased its stake in shares of Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $146,000.

Agios Pharmaceuticals Stock Up 0.3 %

Shares of AGIO stock opened at $55.68 on Friday. The stock’s 50-day moving average price is $47.42 and its 200 day moving average price is $44.51. The stock has a market capitalization of $3.18 billion, a PE ratio of 4.90 and a beta of 0.75. Agios Pharmaceuticals has a 52-week low of $20.96 and a 52-week high of $62.58.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.